Journal of Neural Transmission

, Volume 116, Issue 11, pp 1403–1409

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

Authors

  • D. Zádori
    • Department of Neurology, Albert Szent-Györgyi Clinical CentreUniversity of Szeged
  • P. Klivényi
    • Department of Neurology, Albert Szent-Györgyi Clinical CentreUniversity of Szeged
  • E. Vámos
    • Department of Neurology, Albert Szent-Györgyi Clinical CentreUniversity of Szeged
  • F. Fülöp
    • Department of Pharmaceutical ChemistryUniversity of Szeged
  • J. Toldi
    • Department of Physiology, Anatomy and NeuroscienceUniversity of Szeged
    • Department of Neurology, Albert Szent-Györgyi Clinical CentreUniversity of Szeged
Basic Neurosciences, Genetics and Immunology - Review Article

DOI: 10.1007/s00702-009-0263-4

Cite this article as:
Zádori, D., Klivényi, P., Vámos, E. et al. J Neural Transm (2009) 116: 1403. doi:10.1007/s00702-009-0263-4

Abstract

Parkinson’s, Alzheimer’s and Huntington’s diseases are chronic neurodegenerative disorders of a progressive nature which lead to a considerable deterioration of the quality of life. Their pathomechanisms display some common features, including an imbalance of the tryptophan metabolism. Alterations in the concentrations of neuroactive kynurenines can be accompanied by devastating excitotoxic injuries and metabolic disturbances. From therapeutic considerations, possibilities that come into account include increasing the neuroprotective effect of kynurenic acid, or decreasing the levels of neurotoxic 3-hydroxy-l-kynurenine and quinolinic acid. The experimental data indicate that neuroprotection can be achieved by both alternatives, suggesting opportunities for further drug development in this field.

Keywords

KynureninesKynurenic acidKynurenine aminotransferaseParkinson’s diseaseAlzheimer’s diseaseHuntington’s disease

Copyright information

© Springer-Verlag 2009